United Historical Cash Flow
| UTHR Stock | USD 308.02 2.80 0.90% |
Analysis of United Therapeutics cash flow over time is an excellent tool to project United Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Cash of 514 M or Free Cash Flow of 1.1 B as it is a great indicator of United Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining United Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether United Therapeutics is a good buy for the upcoming year.
United |
About United Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in United balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which United's non-liquid assets can be easily converted into cash.
United Therapeutics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by United Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of United Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from United Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into United Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.At this time, United Therapeutics' End Period Cash Flow is relatively stable compared to the past year. As of 03/29/2025, Depreciation is likely to grow to about 76.1 M, though Other Non Cash Items is likely to grow to (23.1 M).
United Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
United Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
United Therapeutics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 300K | 156.1M | 66.4M | 246.5M | 489.5M | 514.0M | |
| Free Cash Flow | 696.4M | 477.4M | 663.7M | 747.6M | 1.1B | 1.1B | |
| Change In Working Capital | 4.3M | (48.8M) | (35.1M) | (97.8M) | (60.2M) | (57.2M) | |
| Begin Period Cash Flow | 738.4M | 738.7M | 894.8M | 961.2M | 1.2B | 1.3B | |
| Other Cashflows From Financing Activities | 36.8M | 55.6M | 86.8M | 101.9M | 157.4M | 165.3M | |
| Other Non Cash Items | 191.0M | 72.5M | 23.9M | (1.3M) | (24.3M) | (23.1M) | |
| Capital Expenditures | 59.3M | 120.8M | 138.8M | 230.4M | 246.5M | 258.8M | |
| Total Cash From Operating Activities | 755.7M | 598.2M | 802.5M | 978M | 1.3B | 1.4B | |
| Net Income | 514.8M | 475.8M | 727.3M | 984.8M | 1.2B | 1.3B | |
| Total Cash From Financing Activities | (16.9M) | 44.8M | 75.4M | (11.9M) | (1.3B) | (1.2B) | |
| End Period Cash Flow | 738.7M | 894.8M | 961.2M | 1.2B | 1.7B | 1.8B | |
| Sale Purchase Of Stock | (3.7M) | (10.8M) | (11.4M) | (13.8M) | (1.0B) | (961.6M) | |
| Change To Inventory | 10.3M | (7.5M) | (13.4M) | (13.6M) | (46.9M) | (44.6M) | |
| Total Cashflows From Investing Activities | (335.4M) | (738.5M) | (486.9M) | (811.5M) | (730.4M) | (693.8M) | |
| Change To Liabilities | (16.3M) | 38.6M | (12.5M) | 44.5M | 40.1M | 42.1M | |
| Change To Account Receivables | 24.4M | (6M) | (41.3M) | (58.5M) | (400K) | (420K) | |
| Stock Based Compensation | 163.8M | 138.5M | 106.8M | 39.1M | 144M | 94.8M | |
| Investments | (681.6M) | (366.1M) | (683.6M) | (951M) | 417.2M | 438.1M | |
| Change Receivables | 121.4M | 24.4M | (6M) | (41.3M) | (25.0M) | (26.2M) | |
| Net Borrowings | (13.2M) | 599.3M | (51.7M) | (7.5M) | (8.6M) | (8.2M) | |
| Cash And Cash Equivalents Changes | 69.2M | 300K | 156.1M | 66.4M | 59.8M | 52.6M | |
| Cash Flows Other Operating | (201.9M) | 540.7M | 272.6M | 572.2M | 658.0M | 690.9M | |
| Other Cashflows From Investing Activities | (679.2M) | (366.1M) | 3.5M | (23M) | 772.8M | 811.4M | |
| Change To Netincome | 32.9M | 122.2M | 246.7M | 169.6M | 195.0M | 100.5M | |
| Change To Operating Activities | (201.9M) | 16.8M | (112.9M) | (150.6M) | (173.2M) | (181.8M) |
Pair Trading with United Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with United Stock
Moving against United Stock
| 0.59 | LUCD | Lucid Diagnostics | PairCorr |
| 0.56 | WM | Waste Management | PairCorr |
| 0.52 | PG | Procter Gamble Sell-off Trend | PairCorr |
| 0.33 | GE | GE Aerospace | PairCorr |
The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.
The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.